Lead Product(s) : DSR 1.0,Dapagliflozin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Interim results from ten evaluable patients after completion of intensive DSR 1.0 (alfapump DSR Therapy) period demonstrated that DSR therapy safely, effectively and rapidly eliminated persistent congestion and restored euvolemia, resulting in mean weigh...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 19, 2022
Lead Product(s) : DSR 1.0,Dapagliflozin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TB-402
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : BioInvent
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 29, 2011
Lead Product(s) : TB-402
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : BioInvent
Deal Size : Inapplicable
Deal Type : Inapplicable